Want to see HK:1952 full AI Analyst Report?
Total Valuation
Everest Medicines Ltd. has a market cap or net worth of HK$10.58B. The enterprise value is HK$8.57B.
Market CapHK$10.58B
Enterprise ValueHK$8.57B
Share Statistics
Everest Medicines Ltd. has 354,467,070 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding354,467,070
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Everest Medicines Ltd.’s return on equity (ROE) is -0.06 and return on invested capital (ROIC) is -3.16%.
Return on Equity (ROE)-0.06
Return on Assets (ROA)-0.04
Return on Invested Capital (ROIC)-3.16%
Return on Capital Employed (ROCE)-0.06
Revenue Per Employee2.10M
Profits Per Employee-366.71K
Employee Count812
Asset Turnover0.25
Inventory Turnover6.28
Valuation Ratios
The current PE Ratio of Everest Medicines Ltd. is ―. Everest Medicines Ltd.’s PEG ratio is 0.51.
PE Ratio―
PS Ratio6.51
PB Ratio2.09
Price to FCF-64.49
Price to Operating Cash Flow-39.82
PEG Ratio0.51
Income Statement
In the last 12 months, Everest Medicines Ltd. had revenue of 1.71B and earned -297.77M in profits. Earnings per share was -0.89.
Revenue1.71B
Gross Profit1.18B
Operating Income-386.24M
Pretax Income-598.36M
Net Income-297.77M
EBITDA-187.37M
Earnings Per Share (EPS)-0.89
Cash Flow
In the last 12 months, operating cash flow was -183.59M and capital expenditures -98.10M, giving a free cash flow of -281.69M billion.
Operating Cash Flow-183.59M
Free Cash Flow-281.69M
Free Cash Flow per Share-0.79
Dividends & Yields
Everest Medicines Ltd. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.95
52-Week Price Change-48.68%
50-Day Moving Average29.26
200-Day Moving Average33.40
Relative Strength Index (RSI)49.11
Average Volume (3m)7.06M
Important Dates
Everest Medicines Ltd. upcoming earnings date is Apr 1, 2027, Before Open (Confirmed).
Last Earnings DateAug 18, 2026
Next Earnings DateApr 1, 2027
Ex-Dividend Date―
Financial Position
Everest Medicines Ltd. as a current ratio of 4.89, with Debt / Equity ratio of 38.05%
Current Ratio4.89
Quick Ratio4.77
Debt to Market Cap0.08
Net Debt to EBITDA9.64
Interest Coverage Ratio-17.04
Taxes
In the past 12 months, Everest Medicines Ltd. has paid -292.82M in taxes.
Income Tax-292.82M
Effective Tax Rate0.49
Enterprise Valuation
Everest Medicines Ltd. EV to EBITDA ratio is -49.67, with an EV/FCF ratio of -54.01.
EV to Sales5.45
EV to EBITDA-49.67
EV to Free Cash Flow-54.01
EV to Operating Cash Flow-84.63
Balance Sheet
Everest Medicines Ltd. has HK$2.04B in cash and marketable securities with HK$1.99B in debt, giving a net cash position of HK$45.98M billion.
Cash & Marketable SecuritiesHK$2.04B
Total DebtHK$1.99B
Net CashHK$45.98M
Net Cash Per ShareHK$0.13
Tangible Book Value Per ShareHK$9.62
Margins
Gross margin is 69.83%, with operating margin of -22.63%, and net profit margin of -17.45%.
Gross Margin69.83%
Operating Margin-22.63%
Pretax Margin-35.06%
Net Profit Margin-17.45%
EBITDA Margin-10.98%
EBIT Margin-20.15%
Analyst Forecast
The average price target for Everest Medicines Ltd. is HK$54.83, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price TargetHK$54.83
Price Target Upside6.47% Upside
Analyst ConsensusStrong Buy
Analyst Count4
Revenue Growth Forecast192.64%
EPS Growth Forecast92.31%